Follow our Journeys
Sharing success stories internal to Duke Capital Partners and external to our portfolio companies.
Sparta Biomedical spotlighted by World Economic Forum
Sparta Biomedical was recently spotlighted by the World Economic Forum on their Instagram. Read more to see the video and learn more about Sparta Biomedical.
Read More about Sparta Biomedical spotlighted by World Economic Forum
Associate Spotlight: Daniel Luo, Ph.D.
A cancer biologist by training, Daniel joined our team three years ago and has since worked on countless diligence efforts, many of which eventually became our successful portfolio companies.
Duke University researchers have developed a gel-based cartilage substitute
Implants made of the material are currently being developed by Duke Capital Partners portfolio company Sparta Biomedical and tested in sheep. Researchers are gearing up to begin clinical trials in humans next year.
Read More about Duke University researchers have developed a gel-based cartilage substitute
Duke Capital Partners portfolio company, xilis, has closed a $19M+ extension to its Series A financing
xilis is a pioneering biotech company developing its MicroOrganoSphereTM (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development.
InnAVasc Medical, Inc., a Duke Capital Partners portfolio company, has been acquired by W. L. Gore & Associates.
InnAVasc, a Duke Capital Partners portfolio company, has been acquired by W. L. Gore & Associates. Gore will add InnAVasc's dialysis graft tech to its medical advanced materials unit.
Elle Magazine interviews adyn founder Dr. Elizabeth Ruzzo
Congratulations to Duke University alumna Elizabeth Ruzzo, PhD and the entire adyn team on the commercial launch of The Birth Control Test. Read the coverage in ELLE Magazine.
Read More about Elle Magazine interviews adyn founder Dr. Elizabeth Ruzzo